Why the study?
Does the combination of subcutaneous erythropoietin and intravenous iron improve clinical and functional outcomes in anemic patients with severe resistant congestive heart failure?
Does the combination of subcutaneous erythropoietin and intravenous iron improve clinical and functional outcomes in anemic patients with severe resistant congestive heart failure?
Correction of anemia using erythropoietin and intravenous iron in severe, resistant heart failure may improve functional status, cardiac function, and reduce hospitalizations, though larger confirmatory studies are needed.
Answers are grounded in this paper and cite their sources.
May support anemia correction in severe resistant HF; leaves open confirmation in randomized trials.
About one third to one half of patients with heart failure are anemic, in that they have a hemoglobin level of less than 12 g/dL. Anemia is more common and more severe as the clinical status of CHF worsens. In addition, anemia is associated with a higher mortality and higher rate of hospitalization, as well as with signs of malnutrition. In anemic CHF patients who are resistant to maximally tolerated CHF medications and who remain very symptomatic, both uncontrolled studies of a combination of subcutaneous erythropoietin (EPO) and IV ferric sucrose have reported a correction of the anemia. This correction has been associated with an improvement in NYHA functional status, left ventricular ejection fraction, and a marked reduction in the doses of diuretic needed and in the frequency and duration of hospitalizations. Renal function, which had been steadily falling before the correction of the anemia, was also stabilized. Other controlled studies have also found that anemia correction with EPO increased oxygen utilization during maximal exercise, exercise endurance and quality to life. The anemia is probably due mainly to a combination of renal failure and excessive cytokines, both of which interfere with EPO production and utilization. If confirmed by larger studies, correction of anemia with the EPO-IV iron combination may become a useful adjuvant to the treatment of CHF.
No takes yet. Share an insight, caveat, or question.
Dov Wexler (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: